| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.45) per share which met the analyst consensus estimate. This is a 5...
Evoke Pharma surges after QOL Medical announces $11 cash acquisition, a 140% premium, expected to close by the end of 2025.